CEVEC and Catalent offer joint cell line development service
Will generate high expressing stable human cell lines in a much shorter timeframe
CEVEC Pharmaceuticals, the German developer of a novel human protein expression system, and global drug development and delivery solutions provider Catalent Pharma Solutions are to offer a joint commercial cell line development service for pharma and biotech customers worldwide.
The offering combines the benefits of CEVEC’s human cell line, CAP-Technology, with Catalent’s GPEx (Gene Product Expression) Technology to generate high expressing stable human cell lines in a much shorter timeframe than traditional methods.
‘Several months of testing convincingly showed combining CAP cells and GPEx technology is a very powerful approach,’ said Wolfgang Kintzel, managing director of CEVEC. ‘We achieved yields exceeding 3 g/L for a very complex protein produced in our human production cell lines in a very short time frame.
‘The combined offering is a very compelling value proposition for clients looking to outsource cell line development and potential downstream cGMP upscaling while looking for the highest quality using a human cell line.’
‘This exciting collaboration with CEVEC will offer biotech companies developing recombinant proteins and antibodies the advantage of two technologies in one system, enabling them to get a clone candidate in less than five months and significantly reducing their time to clinic,’ stated Scott Houlton, Catalent president, development & clinical services. ‘The GPEx technology has been used to express more than 380 different molecules and our integrated development and manufacturing services allow us to take our customers through their clinical trials in the fastest, most cost effective manner.’
